Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
146.80    -3.80 (-2.52%)
Bid:
148.20
Ask:
150.00
Spread: 1.80 (1.215%)
Market Cap: £250.75m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Acquisition

2 Sep 2010 07:00

RNS Number : 0180S
McBride PLC
02 September 2010
 



2 September 2010

 

McBride plc

 

McBride plc announces the acquisition of Dermacol a.s., a manufacturer of skincare products based in the Czech Republic.

 

McBride plc ("McBride"), Europe's leading provider of Private Label Household and Personal Care products, today announces the acquisition of a 70% interest in Dermacol a.s. ("the Company"), a privately owned, Czech-based manufacturer of skincare products for an expected consideration of around CZK240 million (£8 million) from its parent company Alphaduct a.s. ("Alphaduct"). McBride has also agreed to purchase the remaining 30% of the shares in late 2017 for a consideration based on the Company's operating profit in the 2017 financial year.

 

Acquisition highlights

 

·; Provides McBride with an established private label product range in the largest sector of the European Personal Care market.

 

·; Creates the base for future growth in our skincare business.

 

·; Expands our presence in the growing Central European markets in a low-cost location.

 

Information on Dermacol a.s.

 

Dermacol a.s. is a manufacturer of skincare products, including face creams, skin cleansers, sun care products, body lotions, hand creams and foot creams. Its sales are evenly split between private label products for supermarkets and pharmacy chains and branded products for Alphaduct, which are sold in the Czech Republic and certain other markets. As part of the acquisition agreement, Alphaduct remains the owner of the Dermacol brand and trademarks and it will continue the distribution and marketing of its branded products. Alphaduct has entered into an agreement with the Company to purchase a minimum volume of product on a cost plus basis until 2018.

 

The Company has one factory, which is based near Brno in the Czech Republic and employs over 100 people. It is a modern, well invested factory with significant capacity for expansion. The factory meets ISO 9001 standards and GMP standards required by customers.

 

During the year ended 31 December 2009, the Company reported profit before tax of CZK24 million (£0.8 million). At 31 December 2009, gross assets were CZK 312 million (£10.4 million).

 

Terms of the acquisition

 

The consideration for the initial 70% of the Company's shares comprises:

i. a first payment today of CZK 70 million in cash (£2.3 million); plus

ii. a second payment of CZK 54 million in cash (£1.9 million) payable in August 2011; plus

iii. a further five payments, in cash, payable from 2013 to 2017 inclusive, based on the Company's sales during the period.

 

The expected total consideration of CZK240 million (£8 million) for the initial 70% of shares of the Company will be made from existing Group resources.

 

The remaining 30% of the shares in the Company will be acquired by McBride following the end of the 2017 fiscal year based on the Company's operating profits in that year. The total consideration for the company cannot exceed CZK650 million (£21.7 million).

 

Strategic rationale for the acquisition

 

McBride's strategy is to lead the development of private label household and personal care products in Europe through a focus on organic growth, supplemented by selected acquisitions. Skincare represents 33% of the total European Personal Care market, and is estimated to be worth over 1.1 billion Euros at RSP. Growth of private label has exceeded total personal care growth in the last four years.

 

The Company provides McBride with a range of skincare development and manufacturing capabilities which is highly complementary to its current personal care range. It also provides McBride with a modern, flexible manufacturing plant in a cost competitive region of Europe. The Company will contribute to the significant private label skincare sales forecast for the McBride group, in particular in the UK, France and Germany.

 

Commenting on the acquisition, McBride's chief executive Chris Bull, said:

 

"I am delighted that we have been able to acquire such a high quality skincare company. It is consistent with our stated corporate strategy and provides McBride with a full range of products to create private label skincare ranges for our customers."

 

 

For further information please contact:

 

McBride plc

Chris Bull, Chief Executive

0207 539 7850

Richard Armitage, Finance Director

0207 539 7851

Financial Dynamics

Edward Bridges/Marc Cohen,

020 7831 3113

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQKKDDQFBKDCCK
Date   Source Headline
6th May 20113:43 pmRNSTransfer of Shares out of Treasury
4th May 20113:58 pmRNSHolding(s) in Company
3rd May 201110:29 amRNSTotal Voting Rights
28th Apr 20117:00 amRNSInterim Management Statement
20th Apr 20111:03 pmRNSTransfer of Shares out of Treasury
15th Apr 20114:46 pmRNSHolding(s) in Company
6th Apr 20115:33 pmRNSTransfer of shares into Treasury
4th Apr 20115:17 pmRNSTransfer of Shares into Treasury
1st Apr 20114:32 pmRNSTransaction in Own Shares
1st Apr 20111:44 pmRNSTotal Voting Rights
31st Mar 20117:00 amRNSTransaction in Own Shares
30th Mar 20117:30 amRNSTransaction in Own Shares
25th Mar 20112:11 pmRNSHolding(s) in Company
24th Mar 20114:15 pmRNSResult of General Meeting
18th Mar 20114:24 pmRNSDirector/PDMR Shareholding
10th Mar 20115:18 pmRNSTransaction in Own Shares
28th Feb 20112:09 pmRNSTotal Voting Rights
18th Feb 20112:21 pmRNSHolding(s) in Company
11th Feb 20113:58 pmRNSDirector/PDMR Shareholding
11th Feb 20113:57 pmRNSTreasury Stock
9th Feb 20117:00 amRNSHolding(s) in Company
8th Feb 20117:00 amRNSHalf Year Report
4th Feb 20112:53 pmRNSHolding(s) in Company
1st Feb 20113:51 pmRNSHolding(s) in Company
31st Jan 20117:00 amRNSHolding(s) in Company
27th Jan 20117:00 amRNSAppointment of Non-Executive Director
6th Jan 20117:00 amRNSTrading Update
3rd Dec 201012:18 pmRNSDirector/PDMR Shareholding
30th Nov 201010:27 amRNSTotal Voting Rights
16th Nov 201010:00 amRNSTransaction in Own Shares
29th Oct 201010:56 amRNSTotal Voting Rights
27th Oct 20101:26 pmRNSTransaction in Own Shares
26th Oct 20106:15 pmRNSResult of AGM
26th Oct 20106:15 pmRNSResult of AGM
25th Oct 20107:00 amRNSInterim Management Statement
25th Oct 20107:00 amRNSInterim Management Statement
20th Oct 20103:30 pmRNSHolding(s) in Company
20th Oct 20103:30 pmRNSHolding(s) in Company
13th Oct 20104:49 pmRNSDirector/PDMR Shareholding
13th Oct 20103:37 pmRNSAnnual Information Update
1st Oct 20103:47 pmRNSCompany Secretary Change
24th Sep 20102:59 pmRNSDirector/PDMR Shareholding
24th Sep 201012:28 pmRNSTotal Voting Rights - Correction
23rd Sep 20103:02 pmRNSAnnual Financial Report
23rd Sep 20102:57 pmRNSTotal Voting Rights
16th Sep 20105:33 pmRNSDirector/PDMR Shareholding
14th Sep 201010:09 amRNSDirector Declaration
7th Sep 20102:55 pmRNSHolding(s) in Company
2nd Sep 20107:00 amRNSAcquisition
2nd Sep 20107:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.